Product Images Gemcitabine
View Photos of Packaging, Labels & Appearance
- Chemical Structure - gemcitabine 01
- Figure 1 - gemcitabine 02
- Figure 2 - gemcitabine 03
- Figure 3 - gemcitabine 04
- Figure 4 - gemcitabine 05
- Logo - gemcitabine 06
- PRINCIPAL DISPLAY PANEL - 1 g/26.3 mL Vial Label - gemcitabine 07
- PRINCIPAL DISPLAY PANEL - 1 g/26.3 mL Vial Carton - gemcitabine 08
- PRINCIPAL DISPLAY PANEL - 2 g/52.6 mL Vial Label - gemcitabine 09
- PRINCIPAL DISPLAY PANEL - 2 g/52.6 mL Vial Carton - gemcitabine 10
- PRINCIPAL DISPLAY PANEL - 200 mg/5.26 mL Vial Label - gemcitabine 11
- PRINCIPAL DISPLAY PANEL - 200 mg/5.26 mL Vial Carton - gemcitabine 12
Product Label Images
The following 12 images provide visual information about the product associated with Gemcitabine NDC 0409-0181 by Hospira, Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Figure 1 - gemcitabine 02

This is a comparison of progression-free survival between Gemcitabine/Carboplatin and Carboplatin alone in a study with 178 participants for each treatment. The data includes the median progression-free survival and a graph showing the progression-free survival in months.*
Figure 2 - gemcitabine 03

This text provides a comparison of the median time to documented disease progression between two treatment groups - Paclitaxel alone and Gemcitabine/Paclitaxel combination. The data shows that the median time to documented disease progression for Gemcitabine/Paclitaxel is 5.2 months, while for Paclitaxel alone it is 2.9 months. The p-value from the log-rank test is reported to be less than 0.0001, suggesting a statistically significant difference between the two treatment groups. The findings are based on a sample size of 262 for Paclitaxel and 267 for Gemcitabine/Paclitaxel. Time to documented disease progression in months is graphed over a span of 24 months.*
Figure 3 - gemcitabine 04

This text provides information on the survival probability and median survival time for patients treated with Gem/Cis (combination of Gemcitabine and Cisplatin) compared to Cisplatin alone. The results show that Gem/Cis had a median survival time of 9.0 months with a 39% survival rate, while Cisplatin alone had a median survival time of 7.6 months with a 28% survival rate. The test statistics (Logrank and Wilcoxon) suggest a statistically significant difference between the two treatment groups. Additionally, the data includes the number of patients in each treatment group (N=260 for Gem/Cis and N=262 for Cisplatin) and the 1-year survival rate.*
Figure 4 - gemcitabine 05

This is a list of numerical values, symbols, and a medication name related to a chart or graph possibly showing survival time in months. The values range from 0.0 to 1.0 and there are some numeric values followed by abbreviation of medications "Gemcitabine" and "5-FU". There are also some singular numbers and symbols like 2, 5, @, <, 8, ki, £, [, 1.0, 0.9, and 0.8. This information seems to be a mix of data points and labels for a medical or statistical analysis, possibly related to cancer treatment.*
PRINCIPAL DISPLAY PANEL - 1 g/26.3 mL Vial Carton - gemcitabine 08

This text appears to be a medication label for Gemcitabine injection, containing 195 mg of Gemcitabine hydrochloride per vial. It should be diluted before use and administered intravenously. Gemcitabine is a potentially cytotoxic drug, so precautions should be taken during handling. The product is distributed by Hospira, Inc. It is advisable to store the medication at 2 to 8°C and discard any unused portion. For dosing and administration details, refer to the package insert.*
PRINCIPAL DISPLAY PANEL - 2 g/52.6 mL Vial Carton - gemcitabine 10

This is a medication description for Gemcitabine Injection, which is a potentially cytotoxic drug used intravenously. Each vial contains 2g of gemcitabine. It must be diluted before use and stored at 2 to 8°C. The medication is distributed by Hospira, Inc. under the brand novaplus. Care should be taken to prevent inhaling particles and skin exposure to the drug due to its cytotoxic nature.*
PRINCIPAL DISPLAY PANEL - 200 mg/5.26 mL Vial Carton - gemcitabine 12

This text contains information about a medication called Gemcitabine Injection. It is a cytotoxic agent used for intravenous administration. Each vial contains 200 mg of gemcitabine and must be diluted before use. Care should be taken to prevent inhaling particles or skin exposure. The medication is distributed by Hospira, Inc., and should be stored at 2 to 8°C. Please refer to the package insert for dosing and administration instructions.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.